• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    EVP, President U.S. Healthcare Langowksi Mary covered exercise/tax liability with 40,304 shares, decreasing direct ownership by 8% to 494,295 units (SEC Form 4)

    6/3/25 9:12:39 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
    Get the next $WBA alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Langowksi Mary

    (Last) (First) (Middle)
    C/O WALGREENS BOOTS ALLIANCE, INC.
    108 WILMOT ROAD

    (Street)
    DEERFIELD IL 60015

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Walgreens Boots Alliance, Inc. [ WBA ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    EVP, President U.S. Healthcare
    3. Date of Earliest Transaction (Month/Day/Year)
    06/01/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 06/01/2025 F(1) 40,304 D $11.235 494,295(2) D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Disposition relating to the satisfaction of tax withholding obligations upon the vesting of restricted stock unit award granted in accordance with Rule 16b-3
    2. Includes shares underlying restricted stock units issued in lieu of dividends (through December 31, 2024) on outstanding restricted stock units.
    Remarks:
    /s/ Mary Langowski by Cherita Thomas, Attorney-in-Fact 06/03/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $WBA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $WBA

    DatePrice TargetRatingAnalyst
    2/28/2025$11.00 → $9.00Hold → Sell
    Deutsche Bank
    2/26/2024$23.00Market Perform
    Leerink Partners
    2/20/2024Hold → Reduce
    HSBC Securities
    1/3/2024$21.00Underweight
    Barclays
    12/22/2023$27.00Hold
    HSBC Securities
    10/23/2023$27.00 → $30.00Neutral → Overweight
    JP Morgan
    7/3/2023$37.00 → $27.00Underweight
    Morgan Stanley
    6/28/2023$46.00 → $34.00Buy → Hold
    Deutsche Bank
    More analyst ratings

    $WBA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Walgreens Boots Alliance Reports Fiscal 2025 Third Quarter Results

      Third quarter financial results Third quarter loss per share1 was $0.20 compared to earnings per share of $0.40 in the year-ago quarter. The decline in earnings per share was primarily driven by prior year after-tax gains related to fair value adjustments on variable prepaid forward derivatives and a partial sale of the Company's equity method investment in Cencora, and higher tax expense in the current quarter. Adjusted earnings per share (EPS)2 was $0.38 compared to adjusted EPS2 of $0.63 in the year-ago quarter. The decline in adjusted EPS2 was primarily driven by a higher adjusted effective tax rate2, higher incentive accruals, lower U.S. retail sales and lower equity earnings in

      6/26/25 7:00:00 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Walgreens and KFF's Greater Than Campaign to Offer Free HIV/STD Testing in Stores on June 27

      More than 415 local health departments and community organizations mobilize across the country for largest-ever National HIV Testing Day event Walgreens and Greater Than HIV/STDs, a public information campaign from KFF, are joining with health departments and community organizations to provide free rapid HIV, syphilis and hepatitis C testing at more than 575 Walgreens stores on June 27 for the nation's largest National HIV Testing Day (NHTD) event. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612760766/en/ With more than 415 local testing partners in nearly all states, Washington, D.C. and Puerto Rico, this year's activat

      6/12/25 9:00:00 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • LiveRamp and Walgreens Advertising Group Deliver Business Growth for Advertisers Through Robust Data Collaboration Partnership

      WAG advertisers can now accelerate audience creation, activation, and measurement with flexibility and speed LiveRamp (NYSE:RAMP), the leading data collaboration partner, today announced it is powering Walgreens Advertising Group's (WAG) clean room solution. The partnership enables WAG, the retail media division of Walgreens, to increase access to its first-party data at speed, scale audience insights, and offer more transparency and control to advertisers. This enables brands to enhance media measurement across all platforms in the digital ecosystem and improve ROI with faster time-to-value. LiveRamp's data collaboration network enables WAG to unlock new insights, accelerate performanc

      6/11/25 5:30:00 AM ET
      $RAMP
      $WBA
      EDP Services
      Technology
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples